Using Continuous Glucose Monitoring to Screen for Diabetes in Cystic Fibrosis Patients
Comparison of Continous Glucose Monitor and OGTT as a Screen for Cystic Fibrosis Related Diabetes and Impaired Glucose Tolerance
This study is testing if using continuous glucose monitors can help better screen for diabetes in people with cystic fibrosis.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Medical College of Wisconsin Academic / other |
| Locations | 1 site (Milwaukee, Wisconsin) |
| Trial ID | NCT06560463 on ClinicalTrials.gov |
What this trial studies
This observational study aims to improve the screening process for cystic fibrosis-related diabetes (CFRD) by utilizing continuous glucose monitoring (CGM) alongside the standard oral glucose tolerance test (OGTT). Participants will wear Dexcom G7 sensors for 10 days to track glucose levels, while also undergoing annual OGTT and HgbA1c testing. The clinic's registered dietitian will assist with sensor application, data tracking, and dietary education. Data collected will be analyzed to compare CGM results with traditional screening methods to enhance patient care and adherence.
Who should consider this trial
Good fit: Ideal candidates are adults diagnosed with cystic fibrosis who have normal or impaired glucose tolerance.
Not a fit: Patients diagnosed with cystic fibrosis-related diabetes who are on diabetogenic medications or have undergone transplant will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more accurate and convenient screening for diabetes in cystic fibrosis patients, potentially improving their health outcomes.
How similar studies have performed: While the use of continuous glucose monitoring is gaining traction, this specific approach to screening for CFRD is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. An adult patient, diagnosed with CF, established with Froedtert Multidisciplinary CF Clinic. 2. Normal glucose tolerance or impaired glucose tolerance per OGTT completed in 2024. 3. At healthy baseline status at time of CGM wear and OGTT. Exclusion Criteria: 1. Diagnosed with CFRD and treating with diabetogenic medications. 2. s/p transplant 3. pregnancy 4. failure to wear CGM for entirety of 10 days
Where this trial is running
Milwaukee, Wisconsin
- The Medical College of Wisconsin — Milwaukee, Wisconsin, United States (Recruiting)
Study contacts
- Study coordinator: julie A. Biller, MD
- Email: jbiller@mcw.edu
- Phone: 414-955-7040
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.